Platinol
(Cisplatin)ApprovedSmall molecule
Cisplatin is a chemotherapy drug used to treat various types of cancer, including testicular, ovarian, bladder, and lung cancers by damaging cancer cell DNA and stopping them from growing.[2] Platinol is currently approved and in use across 252 indications[4].[1]
Platinol is one of 2143 small molecule programs targeting Glioma. It is currently in Approved.
252
Indications
2,380
Total Trials
34
Active Trials
2,142
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 251 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Trodelvy
GileadPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer21 trials
Show 18 more trials
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Terminated·—·Phase 2·NCT02157116·13 enrolled
Breast Cancer9 trials
Show 6 more trials
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Withdrawn·—·Phase 1/2·NCT00006123
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Completed·—·Phase 2·NCT00003042·41 enrolled
Small Cell Lung Cancer9 trials
Show 6 more trials
Cervical Cancer9 trials
Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00039338·686 enrolled
Show 6 more trials
Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
Unknown status·—·Phase 2·NCT00008112
BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Terminated·—·Phase 2·NCT03527264·4 enrolled
Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer
Terminated·—·Phase 3·NCT01461772·21 enrolled
Esophageal Cancer6 trials
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
Completed·—·Phase 2·NCT00165490·19 enrolled
82 more indications
Nasopharyngeal Carcinoma6 trials
Head and Neck Cancer6 trials
Show 3 more trials
Gastric Cancer5 trials
Radiation Therapy5 trials
Show 2 more trials
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
Terminated·—·Phase 2·NCT02254681·6 enrolled
Advanced Cancer4 trials
Bladder Cancer4 trials
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04430036·4 enrolled
Induction Chemotherapy4 trials
Multiple Myeloma3 trials
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled
Pancreatic Cancer3 trials
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01296763·18 enrolled
Endometrial Cancer3 trials
Malignant Pleural Mesothelioma3 trials
Squamous Cell Carcinoma3 trials
Neuroblastoma3 trials
Advanced Solid Tumors3 trials
Chemotherapy3 trials
Lymphoma3 trials
Head and Neck Squamous Cell Carcinoma3 trials
Germ Cell Tumor3 trials
Intraperitoneal Chemotherapy2 trials
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Recruiting·—·Phase 2·NCT03127774·30 enrolled
Gastroesophageal Junction Adenocarcinoma2 trials
Urothelial Cancer2 trials
Urothelial Carcinoma2 trials
Patients With Advanced Solid Tumors2 trials
Non-squamous NSCLC2 trials
Patients With Solid Tumors2 trials
Fallopian Tube Cancer2 trials
Locally Advanced2 trials
Cisplatin2 trials
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00882583·22 enrolled
Neoadjuvant Chemotherapy2 trials
Advanced or Metastatic Solid Tumors2 trials
Pleural Mesothelioma2 trials
Chemoradiotherapy2 trials
Esophageal Squamous Cell Carcinoma2 trials
Lung Adenocarcinoma1 trial
Recurrent Cancer1 trial
Transitional Cell Carcinoma1 trial
Immunotherapy1 trial
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Recruiting·—·Phase 2·NCT06725498·50 enrolled
Cervical Carcinoma1 trial
Superior Sulcus Tumor1 trial
Tuvonralimab1 trial
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Recruiting·—·Phase 2·NCT07232654·30 enrolled
Solid Tumors1 trial
Digestive System Neoplasm1 trial
Paclitaxel1 trial
Medulloblastoma1 trial
Maintenance Therapy1 trial
Metastatic Tumors1 trial
Ovarian Cancer1 trial
Efficacy and Safety1 trial
Liver Cancer1 trial
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Completed·—·Phase 1·NCT01042041·18 enrolled
Fluorouracil1 trial
Pleural effusion1 trial
Cancer of the Head and Neck1 trial
Lung Carcinoma1 trial
Gastric Adenocarcinoma1 trial
Metastatic Urothelial Cancer1 trial
Nausea and vomiting1 trial
Oropharyngeal Carcinoma1 trial
Esophageal Adenocarcinoma1 trial
Adjuvant Treatment1 trial
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04455594·168 enrolled
Head Neck Cancer1 trial
Advanced Malignant Solid Tumors1 trial
NSCLC Stage III1 trial
Kidney Cancer1 trial
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
Completed·—·Phase 2·NCT00003928·32 enrolled
Cholangiocarcinoma1 trial
First-line Treatment1 trial
Lung Cancer1 trial
Anaplastic Astrocytoma1 trial
Oropharyngeal Cancer1 trial
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Active, not recruiting·—·Phase 2·NCT06009861·110 enrolled
Malignant Brain Tumors1 trial
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
Unknown status·—·Phase 3·NCT00392886·120 enrolled
Gastroesophageal Junction Cancer1 trial
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01123473·29 enrolled
Organ Preservation1 trial
Melanoma1 trial
Biliary Tract Cancer1 trial
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
Completed·—·Phase 2·NCT00123825·30 enrolled
Regulatory
FDA Approval Timeline[5]
Nov 8, 1988
CISPLATIN
NDA NDA018057
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Platinol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details